EUVIMED · CrossrefZeitschrift
European Urology Oncology
ISSN 2588-9311 · Elsevier BV
Neueste Artikel
Sex-disaggregated Outcomes and Safety Reporting in Perioperative Systemic Therapy for Muscle-invasive Bladder Cancer: A Systematic Review
Impact of BRCA2, BRCA1, and Other Individual Homologous Recombination Repair Alterations on Survival in Metastatic Castration-resistant Prostate Cancer
Clinicopathological Features and Outcomes of Molecularly Confirmed TFE3-rearranged Renal Cell Carcinoma in Adults
Development and Internal Validation of the RMC-COMPASS Clinical Prognostic Model for SMARCB1-deficient Renal Medullary Carcinoma
Adjuvant Pembrolizumab in Patients with Clear Cell Renal Cell Carcinoma: From Eligibility to Individual Treatment Decision
Exploring the Limits of Robotic Surgery for Wilms Tumor: A Descriptive Analysis
Re: Maximilian Pallauf, Stephan Bronimann, Stanley Rapiey, et al. Integrated Urine and Plasma DNA Analysis for Molecular Staging of Upper Tract Urothelial Carcinoma. Eur Urol Oncol. In press. https://doi.org/10.1016/j.euo.2026.08.008
Re: Maximilian Pallauf, Stephan Bronimann, Stanley Rapiey, et al. Integrated Urine and Plasma DNA Analysis for Molecular Staging of Upper Tract Urothelial Carcinoma. Eur Urol Oncol. In press. https://doi.org/10.1016/j.euo.2026.08.008
Corrigendum to “Profiling Fibroblast Growth Factor Receptor 3 Expression Based on the Immune Microenvironment in Upper Tract Urothelial Carcinoma” [European Urology Oncology 7(6) (2024) 1338–1349]
Multiregional Immune Profiling Reveals Prognostic Patterns in Bladder Cancer
Re: Stacy Loeb, Mariana Rangel Camacho, Tatiana Sanchez Nolasco, et al. Downstream Impact of Social Media Use and Variable Quality of Online Information About Prostate Cancer. Eur Urol Oncol 2025;8:1648–52
Diagnostic Value of Fluorine-18-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Staging Histological Subtypes of Invasive Bladder Cancer
Introducing Key Performance Metrics for Assessing the Benefits and Harm of the Prostate Cancer Diagnostic Pathways
Integrating Genomic Prostate Score with Preoperative and Postoperative Cancer of the Prostate Risk Assessment Scores to Predict Biochemical Recurrence after Radical Prostatectomy
Unveiling the Clinical Potential of Prostate Cancer Three-dimensional Models: A Systematic Review
Re: Andrisha-Jade Inderjeeth, Andrew J Martin, Robert R Zielinski et al. Radiographic Progression Without Prostate-specific Antigen Progression in Metastatic Hormone-sensitive Prostate Cancer: A Retrospective Analysis of the ENZAMET Trial (ANZUP 1304). Eur Urol Oncol. In press. http://dx.doi.org/10.1016/j.euo.2026.01.008
Pembrolizumab Plus Lenvatinib in Participants with Docetaxel-pretreated Metastatic Castration-resistant Prostate Cancer: Results from KEYNOTE-365 Cohort E
Salvage High-intensity Focused Ultrasound for Prostate Cancer Recurrence after Radiotherapy (HIFI-2 Study)
MRI Quality and Reader Experience in Organized Prostate Cancer Screening: Insights from the PROBASE Trial
Head-to-head Comparison of Multimodal Imaging for Prostate Cancer Detection and Local Staging with Whole-mount Histopathology Reference
Concomitant MRI-detected and MRI-undetected Prostate Cancer with Implications for Biopsy Strategies and Focal Therapy Planning: An Analysis of the PROMIS and PICTURE Trials
Evaluating the Surrogacy of Pathological Complete Response at Radical Cystectomy in Neoadjuvant-based Muscle-invasive Bladder Cancer Trials
Quality of Life After Postprostatectomy Radiotherapy: A TROG 08.03 RAVES Randomized Controlled Trial Substudy
The Price of Cure: Rethinking Success in High-risk Prostate Cancer
Patient Selection Matters: Who Is Represented in PROTEUS?
Natural History, Tumor Growth Kinetics, and Renal Functional Outcomes of Sporadic Bilateral Multifocal Papillary Renal Cell Carcinoma: A 25-yr Prospective Cohort Study
Re: Parizi MK, D’Andrea D, Pradere B, et al. Prognostic factors for recurrence and survival after radical cystectomy for non-muscle invasive bladder cancer: a multicenter analysis of 1032 patients. Eur Urol Oncol. In press. https://doi.org/10.1016/j.euo.2026.06.001
Long-term Oncological Outcomes of Retzius-sparing Versus Anterior Robot-assisted Radical Prostatectomy: Post Hoc Analysis of a Randomized Cohort
Efficacy of Olaparib Plus Abiraterone for Patients with Metastatic Castration-resistant Prostate Cancer and Single Homologous Recombination Repair Gene Mutations in PROpel
Reply to Pietro Scilipoti, Giuseppe Rosiello, Andrea Salonia, Alberto Briganti, Marco Moschini, Francesco Montorsi Letter to the Editor re: Roberto Contieri, Marco Paciotti, Alessandro Uleri, et al. Second Transurethral Resection of Bladder Tumor Can Be Safely Omitted in Selected Patients with T1 Non–muscle-invasive Bladder Cancer: Results from the Prospective HuNIRe Trial. Eur Urol Oncol 2026;9:404–12
EUVIMED